Phase 2 Study of Combination of Nivolumab and Ipilimumab in (1) Neoadjuvant Setting in Previously Untreated Breast Cancer Patients, (2) Platinum-Resistant/Refractory Advanced Ovarian Cancer Patients; and (3) Advanced Gastric Cancer Patients
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Breast cancer; Gastric cancer; Ovarian cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors ExcellaBio
- 29 May 2019 Status changed from recruiting to discontinued.
- 04 Dec 2017 Status changed from not yet recruiting to recruiting.
- 20 Nov 2017 New trial record